Concentration of lipoprotein - associated phospholipase A2 in chronic dental diseases and stable coronary artery disease

Autor

  • Aleksandra Kimak Chair and Department of Conservative Dentistry with Endodontic, Medical University of Lublin, Poland Autor
  • Bartosz Zięba2 Chair and Department of Laboratory Diagnostic, Medical University of Lublin, Poland Autor
  • Elżbieta Kimak Chair and Department of Laboratory Diagnostic, Medical University of Lublin, Poland Autor
  • Teresa Bachanek Chair and Department of Conservative Dentistry with Endodontic, Medical University of Lublin, Poland Autor

DOI:

https://doi.org/10.12923/j.2084-980X/26.3/a.06

Słowa kluczowe:

lipoprotein-associated phospholipase A2, chronic dental diseases, stable coronary artery disease

Abstrakt

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that has been shown to be a risk factor of cardiovascular disease (CVD) and that is involved in the degradation of the phospholipid mediator platelet-activating factor (PAF), a potent mediator of inflammation. The aim of the present study was to investigate concentration of Lp-PLA2 in control group and patients with chronic dental diseases and stable coronary artery disease (CAD). We studied 10 patients with chronic dental diseases, 10 patients with stable coronary artery disease and 10 healthy individuals as controls. Our patients with stable coronary artery disease were using anti-hypertension medicaments, acetylsalicylic acid and statins although patients with chronic dental diseases were not. A plasma Lp-PLA2 assay kit (ELISA, Human, Life Inc., Wuhan, China) was used. Our results showed that both groups of patients with chronic dental diseases and stable coronary artery disease had significantly increased Lp-PLA2 mass as compared to controls. However, Lp-PLA2 mass in patients with chronic dental diseases and stable coronary artery disease was non-significant statistically. We concluded that patients with chronic dental diseases have increased the serum lipoprotein-associated phospholipase A2, which is believed to be an independent cardiovascular risk factor, although future studies are required.

Bibliografia

1. Caslake M.J., Packard C.J.: Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat. Clin. Pract. Cardiovasc. Med., 2, 529, 2005.

2. Wilensky R.L., Macphee C.H.: Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr. Opin. Lipidol., 20, 415, 2009.

3. Tellis C.C., Tselepis A.D.: The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim. Biophys. Acta, 1791, 327, 2009.

4. Ali M., Madjid M.: Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiol., 2, 159, 2009.

5. Iwase M. et al.: Lysophosphatidylocholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastaine treatment. Atherosclerosis, 196, 931, 2008.

6. Mattila K.J. et al.: Dental infection and the risk of new coronary events: prospective study of patients with documented coronary artery disease. Clin. Infect. Dis., 20, 588, 1995.

7. Teles R., Wang C-Y.: Mechanism involved in the association between periodontal diseases and cardiovascular disease. Oral Dis., 17, 450, 2011.

8. Thompson A. et al.: Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 375, 1536, 2010.

9. Madjid M., Willerson J.T.: Inflammatory markers in coronary heart disease. British Med. Bull., 100, 23, 2011.

10. Daniels L.B. et al.: Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J. Am. Coll. Cardiol., 51, 913, 2008.

11. Löscher W. et al.: Lipoprotein-associated phospholipase A2 and plasma lipids in patients with destructive periodontal disease. J. Clin. Periodontol., 32, 640, 2005.

12. Fentoglu Ö. et al.: Serum lipoprotein-associated phospholipase A2 and C-reactive protein levels in associated with periodontal disease and hyperlipidemia. J. Periodontol., 82, 350, 2011.

13. Zhou S.Y., Xiao W.M., Ouyang X.Y.: Lipoprotein-associated phospholipase A2 and serum lipid levels in subjects with chronic periodontitis and hyperlipidemia. Chin. J. Dent. Res., 15, 25, 2012.

Pobrania

Opublikowane

2013-09-30

Numer

Tom 26 Nr 3 (2013): Current Issues of Pharmacy and Medical Sciences

Dział

Artykuły

Licencja

Prawa autorskie (c) 2013 Autorzy

Creative Commons License

Praca jest udostępniana na licencji Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

Jak cytować

Kimak, A., Zięba2, B., Kimak, E., & Bachanek, T. (2013). Concentration of lipoprotein - associated phospholipase A2 in chronic dental diseases and stable coronary artery disease. Current Issues in Pharmacy and Medical Sciences, 26(3), 273-275. https://doi.org/10.12923/j.2084-980X/26.3/a.06